{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GnRH+Antagonist&page=2",
    "query": {
      "intervention": "GnRH Antagonist",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GnRH+Antagonist&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-29T10:11:29.232Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05057546",
      "title": "Ovarian Hormone Regulation of Central and Cerebrovascular Hemodynamics (NoMEN Study)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Menopause",
        "Estrogen Deficiency",
        "Women",
        "Aging"
      ],
      "interventions": [
        {
          "name": "GnRH antagonist",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 65 Years · Female only"
      },
      "enrollment_count": 55,
      "start_date": "2021-11-22",
      "completion_date": "2025-07-28",
      "has_results": false,
      "last_update_posted_date": "2025-03-27",
      "last_synced_at": "2026-09-29T10:11:29.232Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05057546"
    },
    {
      "nct_id": "NCT04989946",
      "title": "Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Degarelix",
          "type": "DRUG"
        },
        {
          "name": "pTVG-AR",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Cemiplimab",
          "type": "DRUG"
        },
        {
          "name": "Fianlimab",
          "type": "DRUG"
        },
        {
          "name": "FLT PET/CT",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 57,
      "start_date": "2021-12-16",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-07-02",
      "last_synced_at": "2026-09-29T10:11:29.232Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04989946"
    },
    {
      "nct_id": "NCT04856306",
      "title": "Myomectomy vs Uterine Artery Embolization vs GnRh Antagonist for AUB-L",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Heavy Menstrual Bleeding",
        "Fibroid Uterus"
      ],
      "interventions": [
        {
          "name": "Groups 1 and 2 myomectomy and uterine artery embolization, respectively, are surgical/procedure",
          "type": "OTHER"
        },
        {
          "name": "Elagolix Oral Product",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Medstar Health Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 300,
      "start_date": "2021-04-12",
      "completion_date": "2025-08-30",
      "has_results": false,
      "last_update_posted_date": "2022-05-05",
      "last_synced_at": "2026-09-29T10:11:29.232Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04856306"
    },
    {
      "nct_id": "NCT00802360",
      "title": "MENOPUR® Versus FOLLISTIM®",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Infertility"
      ],
      "interventions": [
        {
          "name": "Menotropin",
          "type": "DRUG"
        },
        {
          "name": "Progestrone vaginal insert",
          "type": "DRUG"
        },
        {
          "name": "follitropin beta",
          "type": "DRUG"
        },
        {
          "name": "Progesterone in oil",
          "type": "DRUG"
        },
        {
          "name": "Ganirelix",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ferring Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "42 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 42 Years · Female only"
      },
      "enrollment_count": 173,
      "start_date": "2008-12",
      "completion_date": "2010-01",
      "has_results": true,
      "last_update_posted_date": "2011-11-02",
      "last_synced_at": "2026-09-29T10:11:29.232Z",
      "location_count": 7,
      "location_summary": "Pasadena, California • San Diego, California • Littleton, Colorado + 4 more",
      "locations": [
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Littleton",
          "state": "Colorado"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Naperville",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00802360"
    },
    {
      "nct_id": "NCT07027124",
      "title": "Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer",
        "High-risk Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Darolutamide",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Lupron",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 40,
      "start_date": "2026-05-21",
      "completion_date": "2031-05-02",
      "has_results": false,
      "last_update_posted_date": "2026-06-16",
      "last_synced_at": "2026-09-29T10:11:29.232Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07027124"
    },
    {
      "nct_id": "NCT01696877",
      "title": "A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer Adenocarcinoma in Situ"
      ],
      "interventions": [
        {
          "name": "degarelix acetate",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "GVAX",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "21 Years and older · Male only"
      },
      "enrollment_count": 29,
      "start_date": "2013-01-18",
      "completion_date": "2018-12-18",
      "has_results": true,
      "last_update_posted_date": "2019-03-28",
      "last_synced_at": "2026-09-29T10:11:29.232Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01696877"
    },
    {
      "nct_id": "NCT06111781",
      "title": "The SUGAR Study; SBRT and Relugolix) for Prostate Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Relugolix 120 MG [Orgovyx]",
          "type": "DRUG"
        },
        {
          "name": "SBRT standard of care radiotherapy treatment",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 60,
      "start_date": "2024-04-15",
      "completion_date": "2028-02",
      "has_results": false,
      "last_update_posted_date": "2026-09-14",
      "last_synced_at": "2026-09-29T10:11:29.232Z",
      "location_count": 4,
      "location_summary": "New Haven, Connecticut • Lebanon, New Hampshire • New York, New York + 1 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06111781"
    },
    {
      "nct_id": "NCT06463457",
      "title": "Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer",
        "Advanced Prostate Cancer",
        "Hormone Sensitive Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Darolutamide",
          "type": "DRUG"
        },
        {
          "name": "Relugolix",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Atish Choudhury, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 33,
      "start_date": "2024-12-13",
      "completion_date": "2028-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-03-09",
      "last_synced_at": "2026-09-29T10:11:29.232Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06463457"
    },
    {
      "nct_id": "NCT04173169",
      "title": "Pre-IVF Treatment With a GnRH Antagonist in Women With Endometriosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Infertility",
        "Endometriosis"
      ],
      "interventions": [
        {
          "name": "Elagolix 200 MG",
          "type": "DRUG"
        },
        {
          "name": "Placebo or SOC IVF",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 40 Years · Female only"
      },
      "enrollment_count": 103,
      "start_date": "2022-03-15",
      "completion_date": "2025-05-02",
      "has_results": true,
      "last_update_posted_date": "2026-06-12",
      "last_synced_at": "2026-09-29T10:11:29.232Z",
      "location_count": 5,
      "location_summary": "Aurora, Colorado • New Haven, Connecticut • Chicago, Illinois + 2 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Morrisville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04173169"
    },
    {
      "nct_id": "NCT01327495",
      "title": "PROS-2 Dose Response Effects of Exogenous Testosterone on the Prostate",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "placebo acyline",
          "type": "OTHER"
        },
        {
          "name": "placebo gel",
          "type": "OTHER"
        },
        {
          "name": "Testosterone 1% gel 1.25 g",
          "type": "DRUG"
        },
        {
          "name": "Testosterone 1% gel 2.5 g",
          "type": "DRUG"
        },
        {
          "name": "Testosterone 1% gel 5.0 g",
          "type": "DRUG"
        },
        {
          "name": "testosterone 1% gel 10 g",
          "type": "DRUG"
        },
        {
          "name": "testosterone 1% gel 15 g",
          "type": "DRUG"
        },
        {
          "name": "Acyline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "25 Years to 55 Years · Male only"
      },
      "enrollment_count": 62,
      "start_date": "2011-10",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2017-10-05",
      "last_synced_at": "2026-09-29T10:11:29.232Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01327495"
    }
  ]
}